艾伯維(ABBV.US)料兩新藥年收入逾175億美元 看好治療免疫疾病新藥物
格隆匯1月11日丨美國藥廠艾伯維(ABBV.US)看好治療免疫疾病的新藥物Skyrizi及Rinvoq,認為銷售前景向好,向上修訂兩款新藥2025年收入預測。艾伯維最新估計,兩款新藥在2025年的收入將高於175億美元(下同),原先為高於150億元。Abbvie又估計,新藥2027年收入將超過210億元。艾伯維希望新藥的收入可抵消王牌藥物Humira專利即將屆滿,對集團收入所產生的負面打擊。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.